Call for Science

Submitting an abstract, late-breaking science or a case report to SCAI's Scientific Sessions provides you with the opportunity to share your work with our global community. Share your experience, knowledge, latest clinical data and medical advances with your peers and contribute to improving practice and the patient experience.

Submissions are welcomed from physicians, cardiovascular professionals, hospital administrators, academics, and industry professionals from around the world.

Key dates

Submit Late Breaking Science Now Closed
Abstract Submissions Now Closed
Case Submissions Now Closed
late breaking icon

Late Breaking Science

The Program Committee is looking for late-breaking clinical science, follow-up data from major randomized trials, single or multicenter registries, and first-in-man experiences with novel devices or drugs. Submissions will be considered for oral presentation in a featured session.

  • Submission is FREE!
  • All accepted abstracts will be given the opportunity for simultaneous published in SCAI's official journal, Catheterization and Cardiovascular Interventions (CCI).
  • All accepted presenters receive nontransferable complimentary registration.

Closed

abstract icon

Abstracts

Submissions will be considered for the virtual poster hall and inclusion in the Catheterization and Cardiovascular Interventions (CCI) journal. 

  • Submission is FREE!
  • Accepted presenters must submit a poster and five-minute poster talk to receive nontransferable complimentary registration. 

Closed

clinical case submission icon

Case Submissions

Submissions must include a PowerPoint file and are considered for oral presentation.

  • Submission is FREE!
  • All accepted presenters receive nontransferable complimentary registration.

Closed

Accepted Virtual Poster Presentation Guidelines

Guidelines for preparing your virtual poster presentation: 

  • Create a recording of your slide presentation. Accepted Video Formats: MP4, FBR, MOV. Click here to review virtual posters from SCAI 2020.   
  • Recording must not exceed 10 minutes, the maximum presentation time afforded to virtual posters for SCAI 2021.  
  • Review the quality of recording prior to submitting.  
  • Use the SCAI 2021 PPT template.  
    • Include disclosure information on slide 2.  
    • Include email contact on your last slide.  
  • Questions? Contact Rachel Pham at abstracts@scai.org.

Quick Tips:  

  • Test audio before recording. Tip: A wired headset will produce the best audio quality.  
  • Begin your presentation on your title slide and introduce yourself by name.  
  • A brief pause in-between slide transitions may be needed with some applications.  
  • For detailed technical suggestions please visit the Speaker Service Center and click on “Upload Presentation.” 

Submission:  

  • Presentations are due by 11:59 PM EDT on Monday, April 12, 2021, to be included in the native app launch. 
  • Upload your MP4, FBR, or MOV file and either the PDF or PPT file of your presentation in the speaker service center.
Abstract Guidelines

1.  There is a maximum of three image uploads allowed. The only accepted file formats are JPG, JPEG, PNG, and GIF. There are four sections: Background, Methods, Results, and Conclusions. You are allowed a TOTAL of 1,900 characters for all four sections combined. Please note that each image counts as 500 characters.  

2.  Abstracts that have been previously published or presented will NOT be eligible for presentation at SCAI. If your abstract is accepted for presentation at another meeting or published prior to the SCAI 2021 Scientific Sessions, you must notify SCAI immediately to withdraw your abstract.  

3.  Case studies will NOT be accepted or considered for abstract poster presentation at the SCAI Scientific Sessions. SCAI has a separate call for cases where you should submit your interesting cases and case reports.  

4.  Investigators should not submit the same research; applications that appear to be replicate versions of a single study will be rejected. 

5.  The SCAI Program Committee endorses the position of the American Association for the Advancement for Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must follow these guidelines.  

6.  Abstract submissions must fit into one of the following categories:  

  • Acute Coronary Syndromes & MI  
  • Adult Congenital  
  • Angiogenesis, Myogenesis, Cell Therapy and Gene Therapy  
  • Cardiogenic Shock and Hemodynamic Support  
  • Carotid Interventions  
  • Complex PCI & Restenosis (Excluding Left Main & Multi-Vessel Intervention)  
  • Imaging: CT, MR, and Non-Invasive Imaging  
  • Intervention for Stable Ischemic Heart Disease  
  • Intravascular Imaging (IVUS/OCT/NIR/Other) and Physiology (FFR/iFR/IMR/other)  
  • Left Main & Multi-Vessel Intervention  
  • Miscellaneous  
  • Other Endovascular Interventions (Including Renal Denervation and AAA)  
  • PAD & CLI  
  • Pediatric  
  • Pharmacotherapy  
  • Pulmonary Embolism  
  • Quality Improvement  
  • Structural Heart Disease (Excluding Valvular Interventions)  
  • Thrombectomy and Vulnerable Plaque  
  • Transcatheter Aortic Valve Replacement (TAVR)  
  • Valvular Interventions (Excluding TAVR)  
  • Vascular Access and Arterial Closure Devices  
  • Venous Disease (Including DVT, Insufficiency)  

7.  Each presenting author will be asked to comply with the SCAI Disclosure Policy. Indication of the relationship, the associated commercial entity, and the level of support is required for each presenting author. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information, as applicable, or that they have nothing to disclose.  

8.  There is no limit on number of authors for Abstract Submissions.   

9.  All revisions must be made by the abstract submission deadline.  

10,  The submitter acts on behalf of all co-authors and in submitting an abstract/late-breaking clinical science, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following:  

  • All proprietary rights other than copyright, such as patent rights  
  • The right to use all or part of the application in future works of their own. Catheterization and Cardiovascular Interventions (CCI), as holder of the copyright on the accepted application, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.  

11.  Abstract acceptance notifications will be e-mailed to the addresses provided for the presenting authors along with presentation guidelines.  

12.  Requests to withdraw an abstract must be submitted in writing to abstracts@scai.org by February 28, 2021  

13.  SCAI promotes abstracts, late-breaking clinical science, research, and presentations to online, print, and broadcast media on behalf of Scientific Sessions.  

14.  Embargoed content: All authors, presenters, company sponsors, attendees, journalists, and/or anyone with knowledge of embargoed content must comply with SCAI embargo policies, which state that scientific study results presented during Scientific Sessions must not be released publicly prior to the time of presentation at Scientific Sessions or the SCAI-sponsored press conference, whichever comes first. If the media contacts authors directly, authors, presenters, and/or company sponsors must first seek SCAI approval for information to be shared with the understanding that it is under embargo. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters, and/or company sponsors. The SCAI leadership, press staff, and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., Securities and Exchange Commission requirements) must be met or in the case of public health concern. The embargo on poster presentations lifts when the Poster Session containing the poster opens for viewing. The only exception to the above-mentioned embargo rules are closed investigator meetings for participants in the trial. The Program Committee may ask you to supply investigator meeting date/time/location information if your submission is accepted.

Case Guidelines

1.  A case report and a PowerPoint presentation are required for submission. The Case Report must include the following sections: Title, Introduction, Clinical Case, Discussion. You are allowed a limit of 500 words (not including headers).   

2.  The SCAI Program Committee endorses the position of the American Association for the Advancement for Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must follow these guidelines.  

3.  Case submissions must fit into one of the following categories:  

  • Acute Coronary Syndromes & MI  
  • Adult Congenital  
  • Angiogenesis, Myogenesis, Cell Therapy and Gene Therapy  
  • Cardiogenic Shock and Hemodynamic Support  
  • Carotid Interventions  
  • Complex PCI & Restenosis (Excluding Left Main & Multi-Vessel Intervention)  
  • Imaging: CT, MR, and Non-Invasive Imaging  
  • Intervention for Stable Ischemic Heart Disease  
  • Intravascular Imaging (IVUS/OCT/NIR/Other) and Physiology (FFR/iFR/IMR/other)  
  • Left Main & Multi-Vessel Intervention  
  • Miscellaneous  
  • Other Endovascular Interventions (Including Renal Denervation and AAA)  
  • PAD & CLI  
  • Pediatric  
  • Pharmacotherapy  
  • Pulmonary Embolism  
  • Quality Improvement  
  • Structural Heart Disease (Excluding Valvular Interventions)  
  • Thrombectomy and Vulnerable Plaque  
  • Transcatheter Aortic Valve Replacement (TAVR)  
  • Valvular Interventions (Excluding TAVR)  
  • Vascular Access and Arterial Closure Devices  
  • Venous Disease (Including DVT, Insufficiency)  

4.  Each presenting author will be asked to comply with the SCAI Disclosure Policy. Indication of the relationship, the associated commercial entity, and the level of support is required for each presenting author. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information, as applicable, or that they have nothing to disclose.  

5.  There is no limit on number of authors for Case Submissions.  

6.  All revisions must be made by the case submission deadline.  

7.  The submitter acts on behalf of all co-authors and in submitting a case, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following:  

  • All proprietary rights other than copyright, such as patent rights  
  • The right to use all or part of the application in future works of their own. Catheterization and Cardiovascular Interventions (CCI), as holder of the copyright on the accepted application, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.  

8.  Case acceptance notifications will be e-mailed to the addresses provided for the presenting authors along with presentation guidelines. 

9.  Requests to withdraw a case must be submitted in writing to cases@scai.org by February 28, 2021.  

10.  Embargoed content: All authors, presenters, company sponsors, attendees, journalists, and/or anyone with knowledge of embargoed content must comply with SCAI embargo policies, which state that scientific study results presented during Scientific Sessions must not be released publicly prior to the time of presentation at Scientific Sessions or the SCAI-sponsored press conference, whichever comes first. If the media contacts authors directly, authors, presenters, and/or company sponsors must first seek SCAI approval for information to be shared with the understanding that it is under embargo. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters, and/or company sponsors. The SCAI leadership, press staff, and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., Securities and Exchange Commission requirements) must be met or in the case of public health concern. The embargo on poster presentations lifts when the Poster Session containing the poster opens for viewing. The only exception to the above-mentioned embargo rules are closed investigator meetings for participants in the trial. The Program Committee may ask you to supply investigator meeting date/time/location information if your submission is accepted.  

Questions?

Email: abstracts@scai.org

Phone: 800-992-7224